<DOC>
	<DOCNO>NCT01731249</DOCNO>
	<brief_summary>The purpose 2-year study ass sustain clinical efficacy safety 300 IR/day sublingual solution birch pollen allergen extract start 4 month prior birch pollen season continue birch pollen season compare placebo reduction rhinoconjunctivitis-related symptom anti-allergy medication usage .</brief_summary>
	<brief_title>Efficacy Safety Study Sublingual Immunotherapy Solution Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Symptomatic birch pollenrelated allergic rhinoconjunctivitis least previous 2 pollen season require intake symptomatic treatment . Sensitization birch pollen demonstrate positive Skin Prick Test birch pollen wheal diameter &gt; 3 mm birch pollen allergen specific IgE level ≥ 0.70 kU/L . RRTSS base previous penultimate birch pollen season ≥ 12 maximum possible score 18 . Patients FEV1 ( Forced Expiratory Volume one second ) ≥ 80 % predict value . Patients willing comply protocol . Patients give sign informed consent complete study related procedure . Patients symptoms rhinitis/rhinoconjunctivitis birch pollen season due allergen ( except alder hazel ) . This include patient symptomatic allergic rhinitis/rhinoconjunctivitis due cat dog allergen , live animal home risk frequent contact animal ( family , friends etc . ) course study . Patient previously receive desensitization treatment birch pollen and/or another Betulaceae sp . ( example hazel alder ) within previous 5 year . Patients ongoing treatment immunotherapy another allergen . Pregnancy ( positive pregnancy test ) , breastfeed . Female patient childbearing potential planning pregnancy study use medically accept contraceptive method ( hormonal birth control [ orally , injectable implant , least 2 month enrolment ] , intrauterine device , spermicide use male condom , bilateral tubal ligation , diaphragm spermicide , female condom , monogamous relationship vasectomise partner ) . Patients plan move study planning leave area birch pollen season 1 week ( 7 consecutive day ) . Patients moderate severe persistent asthma ( GINA 3 4 ) . Patients seasonal mild persistent asthma ( GINA 2 ) necessitating treatment inhaled glucocorticosteroids dose level great 400 mcg budesonide doseequivalents . Patients nasal oral condition could interfere efficacy safety assessment ( nasal polyposis oral inflammation ) . Patients severe immune deficiency . Patients past current disease , judge Investigator , may affect patient 's participation outcome study . Any disease condition would place patient undue risk include study ( accord Investigator 's opinion ) . Usual contraindication immunotherapy concomitant betablocker therapy whatever route and/or immunosuppressive drug . Patients treat inhaled/systemic steroid ( whatever indication ) within 4 week prior Visit 1 ( Screening ) , long act systemic corticosteroid 12 week Visit 1 ( Screening ) . Patients continuous corticotherapy ( inhaled systemic drug ) . Patients follow strict low sodium diet study treatment contain 590 mg sodium chloride per vial 10 mL solution . Investigators , coInvestigators , well child spouse study collaborator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Birch pollen extract solution</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>